Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations. (January 2019) - Tanaka, Ichidai; Morise, Masahiro; Kodama, Yuta; Matsui, Akira; Ozawa, Naoya; Ozone, Sachiko; Goto, Daiki; Miyazawa, Ayako; Hase, Tetsunari; Hashimoto, Naozumi; Sato, Mitsuo; Hasegawa, Yoshinori